Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: Retrospective results from six European countries

Bernd Schweikert, David Pittrow, Carmine Dario Vizza, Joanna Pepke-Zaba, Marius M. Hoeper, Anja Gabriel, Jenny Berg, Mirko Sikirica

Research output: Contribution to journalArticle

Abstract

Background: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) results from incomplete resolution of a pulmonary embolus, leading to pulmonary hypertension and progressive right heart failure and death. We aimed to describe the demographics, treatment patterns, health resource utilization and related costs of patients with CTEPH. Methods. In specialized PH centres across six European countries, medical charts of CTEPH patients on PH medication were retrospectively extracted (chart review between 2006 and 2009). Resource utilization was valued using country-specific unit costs. Descriptive statistical analyses were performed. Results: Twenty-one hospitals documented 119 consecutive CTEPH patients over an average of 25.4 months. Patients were inoperable (83.9%) or persistent after surgery (16.0%) with mean age 67.5 ± 12.3 years, 61% were female. The average 6-minute walking distance was 298 ± 120 meters, and NYHA class II/III/IV was 27/59/14%. At baseline, 59.7% patients received endothelin receptor antagonist, 34.4% phosphodiesterase-5 inhibitors, and 5.8% prostacyclin. Adding a second PH medication was the most common regimen change. CTEPH patients experienced 1.8 ± 2.2 hospitalizations per year accounting for 14.8 ± 26.1 days in hospital. Patients paid on average 2.8 office visits per year to their general practitioner and 1.3 visits to a specialist. Unadjusted annual mortality rate was 6.0%. Annual cost of PH specific medication was the predominant economic factor averaging 36,768 per year. Costs for hospitalizations ( 4,496) and concomitant medications ( 2,510) were substantially lower. Other health care resource items only accounted for marginal additional costs. Conclusion: CTEPH patients are characterised by substantial morbidity and mortality. Health care utilisation, predominantly due to off-label use of PH drugs, is significant.

Original languageEnglish
Article number246
JournalBMC Health Services Research
Volume14
Issue number1
DOIs
Publication statusPublished - Jun 9 2014

Keywords

  • Chart review
  • Cost
  • Pulmonary hypertension
  • Retrospective
  • Treatment

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: Retrospective results from six European countries'. Together they form a unique fingerprint.

  • Cite this